Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
Enliven Therapeutics appointed biopharma executive Kristine Ball to its Board of Directors, effective immediately. Ball brings more than 20 years of experience, including CEO roles at Antiva Biosciences and Soteria Biotherapeutics and CFO tenures at Menlo Therapeutics and Relypsa, where she guided the clinical-to-commercial transition.
Key figures
- Drug Name
- relcobatinib (ELVN-001)
- Phase Of Trial
- Phase 3
- Indication
- previously treated chronic myeloid leukemia (CML)
- Trial name
- ENABLE-2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.